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*In vivo* xenograft studies in the NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl (NOG) mice
================================================================================

For the xenograft assay, female NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl (NOG) mice (about 8 weeks of age) were anesthetized with sodium pentobarbital (50 mg/kg) in a sterile environment. Then, OVCAR3, OVCAR3/CTHRC1-siRNA, SKOV3 and SKOV3/pcDNA3.1-CTHRC1 cells (2 × 10^6^) in 50 μl of PBS were subcutaneously injected into the flank of individual NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl (NOG) mice using one-milliliter syringes with hypodermic needles. Different time after inoculation, the mice were killed and tumor tissues were immersed in 10% neutral buffered formalin overnight for the immunohistochemical study. For IHC staining, the primary antibodies were E-cadherin, vimentin, Snail, Slug and Twist (Abcam, USA). Enzyme-linked immunosorbent assay was used to measure the secreted CTHRC1 protein level in the serum. Tumor growth was monitored by a caliper and an IVIS Imaging System (Xenogen). Living Image and Xenogen software was used to analyze the images and bioluminescent signals. We analyzed H&E staining status and BLI images of mice to define tumor metastasis. All animal experiments were performed according to the protocols approved by the medical ethical committee of Sun Yat-sen University.

CTHRC1 is closely associated with EMT status in xenograft models
================================================================

To reveal the role of CTHRC1 in the metastasis and EMT of EOC cells, we explored the metastatic activity of OVCAR3/CTHRC1-siRNA and SKOV3/pcDNA3.1-CTHRC1 in NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl (NOG) mice. We found that OVCAR3/CTHRC1-siRNA cells predominantly localized to tumor nodules in the primary injection sites compared to control. However, SKOV3/pcDNA3.1-CTHRC1 cells formed multiple tumors in the peritoneum cavity. The number of metastatic nodules was measured according to the fluorescence signal and H&E staining. As shown in [Figure 8A](#F1){ref-type="fig"} and [8B](#F1){ref-type="fig"}, SKOV3/pcDNA3.1-CTHRC1 cells formed a greater number of metastases than SKOV3 cells in abdomen (3.00 ± 1.05 vs. 1.30 ± 0.48, *p* \< 0.01, respectively). These *in vivo* results confirmed the role of CTHRC1 in the promotion of EOC invasion.
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